Sun Pharma to Acquire Organon for $11.75 Billion in Cash
Sun Pharma will acquire Organon & Co. for US$11.75 billion in an all-cash deal. Organon, with over 70 products in Women's Health and General Medicines, reported US$6.2 billion in revenue for FY2025. The acquisition aims to enhance Sun Pharma's global scale and product portfolio, with completion expected in early 2027.
This is a major acquisition that will substantially increase Sun Pharma's revenue, global footprint, and market position in key therapeutic areas, indicating a high impact on the company's business.
The acquisition is expected to significantly strengthen Sun Pharma's global position, expand its product portfolio, and drive long-term value creation, indicating a positive outlook.
Sun Pharmaceutical Industries Limited has announced a definitive agreement to acquire Organon & Co. for US$14.00 per share in an all-cash transaction, valuing Organon at an enterprise valuation of US$11.75 billion. Organon, a global healthcare company formed from a spin-off from Merck in 2021, specializes in women's health and general medicines, with a portfolio of over 70 products commercialized across 140 countries.
This acquisition aligns with Sun Pharma's strategy to grow its Innovative Medicines business and strengthens its position in Established Brands/Branded Generics. The combined entity is projected to become one of the top 25 global pharmaceutical companies with combined revenues of US$12.4 billion (based on FY24-25 for Sun Pharma and CY2025 for Organon). It will also establish Sun Pharma as a top-10 global player in biosimilars and a top-3 company in global Women's Health.
The transaction has received approval from the Boards of Directors of both Sun Pharma and Organon. It is subject to customary closing conditions, including regulatory approvals and approval by Organon stockholders. The acquisition is expected to be completed in early 2027. Sun Pharma plans to fund the acquisition through available cash resources and committed financing from banks. For the year ended December 31, 2025, Organon reported US$6.2 billion in revenue and Adjusted EBITDA of US$1.9 billion.
What to do with a filing like this
Sun Pharmaceutical Industries Limited filed this with the NSE as a statutory disclosure, categorised under acquisition. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sun Pharmaceutical Industries Limited. Read the original for the full detail.